Universidad Peruana Cayetano Heredia

A 'Polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America

Mostrar el registro sencillo del ítem

dc.contributor.author Bautista, Leonelo E.
dc.contributor.author Vera-Cala, Lina M.
dc.contributor.author Ferrante, Daniel
dc.contributor.author Herrera, Victor M.
dc.contributor.author Miranda, J. Jaime
dc.contributor.author Pichardo, Rafael
dc.contributor.author Sánchez Abanto, Jorge R.
dc.contributor.author Ferreccio, Catterina
dc.contributor.author Silva, Eglé
dc.contributor.author Arenas, Myriam O.
dc.contributor.author Chirinos, Julio A.
dc.contributor.author Medina-Lezama, Josefina
dc.contributor.author Pérez, Cynthia M.
dc.contributor.author Schapochnik, Norberto
dc.contributor.author Casas, Juan P.
dc.date.accessioned 2022-01-04T20:29:59Z
dc.date.available 2022-01-04T20:29:59Z
dc.date.issued 2013
dc.identifier.uri https://hdl.handle.net/20.500.12866/10488
dc.description.abstract We evaluated the cost-effectiveness of administering a daily “polypill” consisting of three antihypertensive drugs, a statin, and aspirin to prevent cardiovascular disease among high-risk patients in Latin America. We found that the lifetime risk of cardiovascular disease could be reduced by 15 percent in women and by 21 percent in men if the polypill were used by people with a risk of cardiovascular disease equal to or greater than 15 percent over ten years. Attaining this goal would require treating 26 percent of the population at a cost of $34–$36 per quality-adjusted life-year. Offering the polypill to women at high risk and to men age fifty-five or older would be the best approach and would yield acceptable incremental cost-effectiveness ratios. The polypill would be very cost-effective even in the country with the lowest gross national income in our study. However, policy makers must weigh the value of intervention with the polypill against other interventions, as well as their country’s willingness and ability to pay for the intervention. en_US
dc.language.iso eng
dc.publisher Project HOPE
dc.relation.ispartofseries Health Affairs
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Latin America en_US
dc.subject Antihypertensive Agents en_US
dc.subject Humans en_US
dc.subject cost effectiveness analysis en_US
dc.subject Risk Factors en_US
dc.subject cardiovascular disease en_US
dc.subject Developing Countries en_US
dc.subject hydroxymethylglutaryl coenzyme A reductase inhibitor en_US
dc.subject primary prevention en_US
dc.subject Drug Combinations en_US
dc.subject South and Central America en_US
dc.subject Cohort Studies en_US
dc.subject quality of life en_US
dc.subject health care cost en_US
dc.subject risk reduction en_US
dc.subject Randomized Controlled Trials as Topic en_US
dc.subject risk benefit analysis en_US
dc.subject cardiovascular risk en_US
dc.subject high risk patient en_US
dc.subject acetylsalicylic acid en_US
dc.subject Aspirin en_US
dc.subject Cost-Benefit Analysis en_US
dc.subject Atenolol en_US
dc.subject Hydroxymethylglutaryl-CoA Reductase Inhibitors en_US
dc.subject Markov Chains en_US
dc.subject Quality-Adjusted Life Years en_US
dc.subject Ramipril en_US
dc.subject Simvastatin en_US
dc.subject Sodium Chloride Symporter Inhibitors en_US
dc.subject ST segment elevation myocardial infarction en_US
dc.title A 'Polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1377/hlthaff.2011.0948
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.04
dc.relation.issn 1544-5208


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas